Literature DB >> 30550772

m6A modification of non-coding RNA and the control of mammalian gene expression.

Heather Coker1, Guifeng Wei2, Neil Brockdorff2.   

Abstract

The biology of non-coding RNA (ncRNA) and the regulation of mammalian gene expression is a rapidly expanding field. In this review, we consider how recent advances in technology, enabling the precise mapping of modifications to RNA transcripts, has provided new opportunities to dissect post-transcriptional gene regulation. With this has come the realisation that in the absence of translation, the modification of ncRNAs may play a fundamental role in their regulation, protein interactome and subsequent downstream effector functions. We focus upon modification of RNA by N6-methyladenosine (m6A); its readers, writers and erasers, before considering the differing role of m6A modified lncRNAs MALAT1 and Xist. This article is part of a Special Issue entitled: mRNA modifications in gene expression control edited by Dr. Soller Matthias and Dr. Fray Rupert. Crown
Copyright © 2018. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MALAT1; Xist; m6A; ncRNA

Mesh:

Substances:

Year:  2018        PMID: 30550772     DOI: 10.1016/j.bbagrm.2018.12.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gene Regul Mech        ISSN: 1874-9399            Impact factor:   4.490


  45 in total

1.  Structural effects of m6A modification of the Xist A-repeat AUCG tetraloop and its recognition by YTHDC1.

Authors:  Alisha N Jones; Ekaterina Tikhaia; André Mourão; Michael Sattler
Journal:  Nucleic Acids Res       Date:  2022-02-28       Impact factor: 16.971

2.  Development and validation of prognostic m6A-related lncRNA and mRNA model in thyroid cancer.

Authors:  Yu Zhu; Tian Yu; Ju Huang; Xitao Ma; Tao Shen; Annuo Li; Rensong Yue
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

3.  N6-methyladenosine regulates maternal RNA maintenance in oocytes and timely RNA decay during mouse maternal-to-zygotic transition.

Authors:  You Wu; Xiaocui Xu; Meijie Qi; Chuan Chen; Mengying Li; Rushuang Yan; Xiaochen Kou; Yanhong Zhao; Wenqiang Liu; Yanhe Li; Xuelian Liu; Meiling Zhang; Chengqi Yi; Hongbin Liu; Junhong Xiang; Hong Wang; Bin Shen; Yawei Gao; Shaorong Gao
Journal:  Nat Cell Biol       Date:  2022-05-23       Impact factor: 28.213

Review 4.  Progress and application of epitranscriptomic m6A modification in gastric cancer.

Authors:  Yitian Xu; Chen Huang
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.766

Review 5.  Epigenetic regulations in mammalian spermatogenesis: RNA-m6A modification and beyond.

Authors:  Yiqian Gui; Shuiqiao Yuan
Journal:  Cell Mol Life Sci       Date:  2021-04-09       Impact factor: 9.261

6.  Identifying cortical specific long noncoding RNAs modified by m6A RNA methylation in mouse brains.

Authors:  Yanzhen Nie; Geng G Tian; Longbin Zhang; Trevor Lee; Zhen Zhang; Jing Li; Tao Sun
Journal:  Epigenetics       Date:  2020-12-23       Impact factor: 4.528

Review 7.  Role of m6A in osteoporosis, arthritis and osteosarcoma (Review).

Authors:  Yibo Hu; Xiaohui Zhao
Journal:  Exp Ther Med       Date:  2021-06-30       Impact factor: 2.447

8.  METTL3-Mediated lncRNA m6A Modification in the Osteogenic Differentiation of Human Adipose-Derived Stem Cells Induced by NEL-Like 1 Protein.

Authors:  Yidan Song; Yihua Pan; Mengsong Wu; Wentian Sun; Liangyu Luo; Zhihe Zhao; Jun Liu
Journal:  Stem Cell Rev Rep       Date:  2021-09-10       Impact factor: 5.739

9.  N6-methyladenosine methyltransferase WTAP-stabilized FOXD2-AS1 promotes the osteosarcoma progression through m6A/FOXM1 axis.

Authors:  Zhipeng Ren; Yongcheng Hu; Jie Sun; Yuxiang Kang; Guishi Li; Hejun Zhao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 10.  RNA modifications act as regulators of cell death.

Authors:  Lei Xu; Chong Zhang; Hang Yin; Shuai Gong; Nai Wu; Zeqiang Ren; Yi Zhang
Journal:  RNA Biol       Date:  2021-07-27       Impact factor: 4.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.